|Bid||140.23 x 100|
|Ask||140.33 x 100|
|Day's Range||139.86 - 144.67|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||60.92|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alexion Pharmaceuticals Inc (NASDAQ:ALXN) generated a below-average return on equity of 6.11% in the past 12 months, while its industry returned 15.86%. An investor may attribute an inferior ROE toRead More...
Alexion Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Over the last one-month, outflows of investor capital in ETFs holding ALXN totaled $6.54 billion.
In 2Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenues of ~$83 million, which was ~84% higher YoY and ~12% higher QoQ.
In 2Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenues of ~$814 million, which represented a ~16% YoY rise and a ~4% QoQ rise.
In 2Q17, Alexion Pharmaceuticals (ALXN) generated revenues of ~$912 million, which was ~21% higher YoY (year-over-year) and ~5% higher QoQ.
In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals' (ALXN) Soliris.
The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Alexion Pharmaceuticals, Inc. a score of 69. Our analysis is based on comparing Alexion Pharmaceuticals, Inc. with the following peers – Celgene Corporation, Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, Intrexon Corporation, Biogen Inc., QIAGEN NV, Ultragenyx Pharmaceutical, Inc. and Agios Pharmaceuticals, ... Read more (Read more...)
Here is a look at three biotech and pharma stocks including Flexion (FLXN) that have an important regulatory event lined up this month.
Roivant and Moderna, two of the most highly-funded private biotech companies, appear to engaged in a proxy war over medical technology and headed for a showdown.
Alexion Pharmaceuticals Inc (NASDAQ:ALXN) trades with a trailing P/E of 59.4x, which is higher than the industry average of 33.7x. While ALXN might seem like a stock to avoid orRead More...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alexion Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Over the last one-month, outflows of investor capital in ETFs holding ALXN totaled $9.08 billion.
Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Innoviva shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.
Infinity (INFI) expanded its existing clinical collaboration with Bristol-Myers Squibb for evaluating IPI-549 in combination with Opdivo to include patients with triple negative breast cancer.
A Relative Strength Rating upgrade for Acorda Therapeutics shows improving technical performance. Will it continue?
AbbVie (ABBV) and Bristol-Myers Squibb entered into a deal to evaluate the combination of ABBV-399 and Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer.
The Medicines Co.'s (MDCO) divestment of non-core assets should allow the company to focus on key assets and brings in a non-dilutive source of funds as well.